共 50 条
- [26] Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China Cost Effectiveness and Resource Allocation, 21
- [29] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan Journal of Gastroenterology, 2019, 54 : 558 - 570